Maxigen Biotech Inc. (TPE:1783)
Taiwan · Delayed Price · Currency is TWD 40.90
+0.90 (2.25%)
Aug 19, 2026, 1:30 PM CST
Maxigen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 837.44 | 811.56 | 680.65 | 622.12 | 604.43 | 511.98 |
| 837.44 | 811.56 | 680.65 | 622.12 | 604.43 | 511.98 | |
Revenue Growth | 9.39% | 19.23% | 9.41% | 2.93% | 18.06% | 11.86% |
Cost of Revenue | 252.01 | 247.84 | 197.33 | 198.02 | 230.44 | 250.95 |
Gross Profit | 585.43 | 563.72 | 483.33 | 424.09 | 373.99 | 261.03 |
Selling, General & Admin | 173.31 | 183.89 | 176.98 | 205.45 | 141.03 | 92.38 |
Research & Development | 151.36 | 126.11 | 111.97 | 68.6 | 99.63 | 75.68 |
Operating Expenses | 330.61 | 302.68 | 303.42 | 274.24 | 245.38 | 171.08 |
Operating Income | 254.82 | 261.04 | 179.91 | 149.85 | 128.62 | 89.95 |
Interest Expense | -0.2 | -0.04 | - | - | -0.07 | -0.2 |
Interest & Investment Income | 37.06 | 35.28 | 27.43 | 25.02 | 3.18 | 0.48 |
Currency Exchange Gain (Loss) | 3.83 | 3.83 | 17.14 | 4 | 31.69 | -3.6 |
Other Non Operating Income (Expenses) | 29.42 | 4.78 | 1.05 | 0.66 | 1.08 | 10.84 |
EBT Excluding Unusual Items | 324.92 | 304.89 | 225.53 | 179.53 | 164.5 | 97.47 |
Gain (Loss) on Sale of Investments | - | - | 0.02 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0 | 13.62 | 1.03 | - |
Other Unusual Items | - | - | - | - | 0.26 | - |
Pretax Income | 324.92 | 304.89 | 225.55 | 193.14 | 165.78 | 97.47 |
Income Tax Expense | 33.73 | 39.58 | 35.38 | 27.31 | 26.38 | 9.8 |
Net Income | 291.2 | 265.31 | 190.17 | 165.83 | 139.4 | 87.67 |
Net Income to Common | 291.2 | 265.31 | 190.17 | 165.83 | 139.4 | 87.67 |
Net Income Growth | 39.96% | 39.52% | 14.68% | 18.95% | 59.01% | 38.47% |
Shares Outstanding (Basic) | 90 | 90 | 89 | 89 | 89 | 84 |
Shares Outstanding (Diluted) | 91 | 90 | 90 | 89 | 89 | 85 |
Shares Change | 0.33% | 0.77% | 0.27% | 0.07% | 5.78% | 4.81% |
EPS (Basic) | 3.25 | 2.96 | 2.13 | 1.86 | 1.57 | 1.04 |
EPS (Diluted) | 3.22 | 2.94 | 2.12 | 1.85 | 1.56 | 1.04 |
EPS Growth | 38.43% | 38.68% | 14.59% | 18.59% | 50.28% | 31.75% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 243.64 | 208.36 | 266.45 | 148.76 | 254.05 | 103.34 |
Free Cash Flow Per Share | 2.69 | 2.31 | 2.97 | 1.66 | 2.84 | 1.22 |
Dividend Per Share | - | 2.000 | 0.830 | 1.000 | 0.476 | - |
Dividend Growth | - | 140.96% | -17.00% | 110.00% | -24.65% | - |
Gross Margin | 69.91% | 69.46% | 71.01% | 68.17% | 61.88% | 50.98% |
Operating Margin | 30.43% | 32.16% | 26.43% | 24.09% | 21.28% | 17.57% |
Profit Margin | 34.77% | 32.69% | 27.94% | 26.66% | 23.06% | 17.12% |
Free Cash Flow Margin | 29.09% | 25.67% | 39.15% | 23.91% | 42.03% | 20.18% |
EBITDA | 291.32 | 293.07 | 206.75 | 177.09 | 156.71 | 119.73 |
EBITDA Margin | 34.79% | 36.11% | 30.38% | 28.47% | 25.93% | 23.39% |
D&A For EBITDA | 36.5 | 32.03 | 26.85 | 27.24 | 28.09 | 29.79 |
EBIT | 254.82 | 261.04 | 179.91 | 149.85 | 128.62 | 89.95 |
EBIT Margin | 30.43% | 32.16% | 26.43% | 24.09% | 21.28% | 17.57% |
Effective Tax Rate | 10.38% | 12.98% | 15.69% | 14.14% | 15.91% | 10.05% |